<DOC>
	<DOCNO>NCT02539940</DOCNO>
	<brief_summary>The aim observational study evaluate outcome safety Paclitaxel-eluted balloon catheter ELUTAX SV treatment peripheral arterial disease ( PAD ) below-the-knee vessel</brief_summary>
	<brief_title>Elutax-SV Drug-eluting Balloons Below-the-knee Treatment</brief_title>
	<detailed_description>The management critical limb ischemia due below-the-knee disease remain challenge due frequent patient comorbidities , diffuse vascular involvement , limb preservation , high rate restenosis disease progression . This study record use ELUTAX SV-DEB real life condition representative sample.The investigator generate new data observe outcome safety Elutax SV drug-eluting balloon change Rutherford clinical category baseline 6 12 month follow-up visit .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Paclitaxeleluting balloon angioplasty belowtheknee lesion ELUTAX SVDEB Age ≥ 18 year Signed informed consent document Critical Limb Ischemia ( CLI ) target limb prior study Rutherford Category 4 , 5 6 ≥70 % diameter stenosis occlusion target lesion , include denovo / instent restenosis/occlusion target lesion Patent inflow artery Target vessel ( ) diameter 2 4 mm Target vessel ( ) reconstitute ( ) ankle Life expectancy 50 % within next 12 month ( judge investigator ) Planned major index limb amputation Acute limb ischemia ( within last 14 day thrombectomy , atherectomy , lysis ) Application DEBeluting balloon except ELUTAX SV target limb ( POBA allow ) Patient unwilling unlikely comply followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Below-the-knee</keyword>
</DOC>